Premium
O2‐02‐08: Requiring a CSF amyloid‐β 42 biomarker for a prodromal AD research diagnosis does not result in better clinical trials: Simulations from the ADNI database
Author(s) -
Schneider Lon S.,
Kennedy Richard E.,
Cutter Gary R.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.313
Subject(s) - clinical trial , medicine , neuroimaging , biomarker , alzheimer's disease neuroimaging initiative , placebo , dementia , oncology , database , randomized controlled trial , disease , pathology , psychiatry , biochemistry , chemistry , alternative medicine , computer science